12:20 PM EST - ProMIS Neurosciences, Inc. : And its collaborator BC Neuroimmunology Lab Inc., have created a highly accurate antibody test for SARS CoV-2. In validation testing, the serology assay achieved accuracy comparable to that of the industry leaders. Incorporation of ProMIS’ proprietary peptide antigens in the next phase of development is anticipated to support determination of whether or not antibodies detected in the serology assay possess virus neutralizing activity. ProMIS Neurosciences, Inc.
shares T.PMN are trading up $0.055 at $0.24.
